To test whether T.eff score predicts the efficacy of immunotherapy in human tumors, we analyzed a public dataset of patients with advanced bladder cancer (BLCA) before and after anti–PD-1 therapy. The gene discussed is PDCD1; the disease is urinary bladder carcinoma.